Want to join the conversation?
$VRTX said the U.S. FDA accepted a supplemental New Drug Application for review for the use of its ORKAMBI drug in people with cystic fibrosis, a type of genetic disease, ages 6 to 11 who have two copies of the F508del mutation. The FDA granted the company's request for Priority Review of this sNDA, and a target review date of September 30, 2016.
$DB is going to cut off services for about 3,400 clients in equities trading.
$F stock slid more than 2% after the company issued two safety recalls involving more than 650,000 Ford Fusion and Lincoln MKZ model cars.
The new CEO of $SBUX, Kevin Johnson, has some pretty large shoes to fill but there are many who have good faith in his ability to do so.
$TSLA opening a showroom in Michigan. A bold move !!